Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region

International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels: Int’l. Diabetes Federation; 2013. Available from http://www.idf.org/diabetesatlas. Accessed 20 December 2015.

Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the [email protected] study. Diabetologia. 2012;55:88–93.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–986

The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53 [Erratum, Lancet 1999;354:602.].

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713

Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131:446–52.

American Diabetes Association. Glycemic targets. Diabetes Care. 2015;38 Suppl 1:S33–40. doi: 10.2337/dc15-S009 .

American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2015;38 Suppl 1:S49–57. doi: 10.2337/dc15-S011 .

de Sanidad M. Estrategia en Diabetes del Sistema Nacional de Salud. Actualizazión. Madrid: Centro de Publicaciones; 2012.

National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: R.C.P; 2008.

Vinagre I, Mata-Cases M, Hermosilla E, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care. 2012;35:774–9.

Orozco-Beltrán D, Gil-Guillen VF, Quirce F, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007;61:909–15.

Aizpuru F, Latorre A, Ibáñez B, et al. Variability in the detection and monitoring of chronic patients in primary care according to what is registered in the electronic health record. Fam Pract. 2012;29:696–705.

Rothe U, Müller G, Schwarz PE, et al. Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research. Diabetes Care. 2008;31:863–8.

European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818. doi: 10.1093/eurheartj/ehr158 .

Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960–8. doi: 10.1093/eurheartj/ehu107 .

Collier A, Ghosh S, Hair M, Waugh N. Gender differences and patterns of cardiovascular risk factors in Type 1 and Type 2 diabetes: a population-based analysis from a Scottish region. Diabet Med. 2015;32:42–6.

Schütt M, Zimmermann A, Hood R, et al. Gender-specific effects of treatment with lifestyle, Metformin or sulfonylurea on glycemic control and body weight: a German multicenter analysis on 9 108 patients. Exp Clin Endocrinol Diabetes. 2015;123:622–6. doi: 10.1055/s-0035-1559608Exp .

Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the guideline adherence to enhance Care (GUIDANCE) study. Diabetes Care. 2013;36:2628–38.

Franch-Nadal J, Mata-Cases M, Vinagre I, et al. Differences in the Cardiometabolic control in Type 2 diabetes according to gender and the presence of cardiovascular disease: results from the eControl study. Int J Endocrinol. 2014;2014:131709. doi: 10.1155/2014/131709 .

Braga MF, Casanova A, Teoh H, et al. Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract. 2012;66:457–64. doi: 10.1111/j.1742-1241.2012.02894 .

Ali MK, Bullard KM, Saaddine JB, et al. Achievement of Goals in U.S. Diabetes Care, 1999–2010. N Engl J Med. 2013;368:1613–24.

Göbl CS, Brannath W, Bozkurt L, et al. Sex-specific differences in glycemic control and cardiovascular risk factors in older patients with insulin-treated type 2 diabetes mellitus. Gend Med. 2010;7:593–9. doi: 10.1016/j.genm.2010.11.003 .

Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.

Peters SAE, Huxley RR, Sattar N, Woodward M. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep. 2015;9:36.